Lumosa Therapeutics Co., Ltd. and its parent company, Center Laboratories Group, jointly led a Pre-A+ Series A round for GenEditBio, a Hong Kong-based gene-editing company, raising tens of millions of US dollars. Qiming Venture Partners and several Hong Kong government venture capital funds participated in the round. This marks GenEditBio's first foray into gene therapy, and Lumosa leverages this opportunity to expand its research and development of stroke assets and strategically position its product pipeline. GenEditBio specializes in the development of next-generation gene-editing tools and delivery systems, with potential for clinical translation. The global gene therapy market is projected to grow at an average annual rate of 13.9% through 2032. Lumosa's investment demonstrates its foresight and cross-disciplinary innovation.